Atlas Trials

Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer

Clinical trial NCT05705401 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05705401
Sponsor
NRG Oncology
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
HER2-positive Breast Cancer
Start date
2023-05-19
Primary completion
2034-02-01
Enrollment
1300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.